Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$5.83 USD
-0.09 (-1.52%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $5.82 -0.01 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TRDA 5.83 -0.09(-1.52%)
Will TRDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRDA
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
TRDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?
Other News for TRDA
Tracking Baker Brothers Portfolio - Q1 2025 Update
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting
Entrada Therapeutics Appoints New Board Member
Entrada Therapeutics (TRDA) Welcomes New Board Member | TRDA Stock News
Entrada Therapeutics appoints Radhakrishnan to board of directors